Effects of switching from anastrozole to letrozole, due to reimbursement policy, on the outcome of breast cancer therapy
Potchavit Aphinives, Damnern Vachirodom, Chaiyut Thanapaisal, Dhanes Rangsrikajee, Ongart Somintara Department of Surgery, Faculty of Medicine, Khon Kaen University, Thailand Background: Endocrine therapy is one of the standard treatments for estrogen-receptor-positive breast cancer patients. Letr...
Guardado en:
Autores principales: | Aphinives P, Vachirodom D, Thanapaisal C, Rangsrikajee D, Somintara O |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b8cfaf23015c4814a7c692cd38ae5aa8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients
por: Aphinives P, et al.
Publicado: (2015) -
Surgery to Oligometastatic Breast Cancer after Excellent Response to Palbociclib and Letrozole Therapy: Pitfall of Ultrasound Therapeutic Evaluation
por: Suzuka Fujii, et al.
Publicado: (2021) -
Radiation recall dermatitis following letrozole administration in patient with a remote history of radiation therapy
por: Evan Sweren, et al.
Publicado: (2021) -
Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer
por: Merriam PA, et al.
Publicado: (2011) -
The impact of drug reimbursement policy on rates of testosterone replacement therapy among older men.
por: Jolanta Piszczek, et al.
Publicado: (2014)